Bellerophon Therapeutics (NASDAQ:BLPH) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research report sent to investors on Wednesday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Performance

Shares of NASDAQ:BLPH opened at $0.04 on Wednesday. The firm has a market cap of $440,388.00, a PE ratio of -0.04 and a beta of 0.70. The firm’s 50 day simple moving average is $0.04 and its 200-day simple moving average is $0.05. Bellerophon Therapeutics has a one year low of $0.03 and a one year high of $0.10.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.